A recent study has now compared the overall cost of TMS treatment with standard pharmacological interventions for the disorder (i.e. antidepressant medications), taking into consideration direct financial cost as well as “Quality Adjusted Life Years” (QALYs). Given current costs of treatment, the findings show that TMS is more cost-effective over the life-span of adults with MDD, compared to antidepressant medication trials.
However, in many countries TMS is usually only recommended for patients after having failed several antidepressant medication trials. These findings therefore support TMS being a recommended earlier in a patient’s treatment journey, given it is found to be more cost effective than standard pharmacological interventions for MDD.
Source: Voigt, Carpenter & Leuchter (2017)
“Cost effectiveness analysis comparing repetitive transcranial magnetic stimulation to antidepressant medications after a first treatment failure for major depressive disorder in newly diagnosed patients – A lifetime analysis”
In this study rTMS is found to be more cost-effective as a therapy compared to antidepressant medication trials over the life of the patient across the lifespan of adults with Major Depressive Disorder.
neuroCare is a global brand in neuromodulation, active in research training in medication-free applications of TMS and Neurofeedback for mental wellness. neuroCare operates therapy centers all over the world, with clinics now open across Sydney and Melbourne.
neuroCare is innovating mental health and performance by personalising therapy following a detailed assessment. neuroCare’s objective, measurable and effective approach is based on our natural ability to learn (neuroplasticity) and technology to accelerate the learning (neuromodulation).